Evidence map›Paper›PMID 32463871›Full record

ArticleBlood advances2020

Outcomes associated with apixaban vs warfarin in patients with renal dysfunction.

Claudia Hanni, Elizabeth Petrovitch, Mona Ali, Whitney Gibson, Christopher Giuliano, Jenna Holzhausen, Charles Makowski, Amy Pallisco, Nisha Patel, Denise Sutter and 2 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Anticoagulation in Patients with Chronic Kidney Disease.American journal of nephrology · 2024
    Review
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Claudia HanniPharmacy Department, Beaumont Health, Royal Oak, MI.
Elizabeth PetrovitchPharmacy Department, Detroit Medical Center, Detroit, MI.
Mona AliPharmacy Department, Beaumont Health, Royal Oak, MI.
Whitney GibsonPharmacy Department, Baycare Health Systems, St. Petersburg, FL.
Christopher GiulianoWayne State University Eugene Applebaum College of Pharmacy, Detroit, MI.
Jenna HolzhausenPharmacy Department, Beaumont Health, Royal Oak, MI.
Charles MakowskiPharmacy Department, Henry Ford Hospital, Detroit, MI.
Amy PalliscoPharmacy Department, Detroit Medical Center, Detroit, MI.
Nisha PatelPharmacy Department, Henry Ford Hospital, Detroit, MI.
Denise SutterPharmacy Department, Detroit Medical Center, Detroit, MI.
Long ToPharmacy Department, Henry Ford Hospital, Detroit, MI.
Raymond YostPharmacy Department, Detroit Medical Center, Detroit, MI.
Detroit Medical Center · USBeaumont Health · USHenry Ford Hospital · USBayCare Health System · USEugene Applebaum College of Pharmacy and Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apixaban in patients with impaired renal function is supported by limited data. Landmark clinical trials evaluating apixaban in patients with atrial fibrillation and/or acute venous thromboembolism excluded patients with creatinine clearance (CrCl) <25 mL/min. This multicenter, retrospective chart review was conducted to evaluate the safety and effectiveness of apixaban compared with warfarin in patients with CrCl <25 mL/min. Included patients were newly initiated on apixaban or warfarin for at least 45 days with a CrCl <25 mL/min. Patients were evaluated for thrombosis and bleeding outcomes 6 months following initiation of anticoagulation. The primary outcome was the time to first bleeding or thrombosis event. A total of 128 patients met inclusion criteria in the apixaban group and 733 patients in the warfarin group. Time to first bleeding or thrombosis event was significantly different between the apixaban and warfarin groups. Cox proportional hazards model was conducted to control for potential confounding factors for the primary outcome. After controlling for atrial fibrillation and coronary artery bypass grafting, risk of thrombotic and bleeding events was lower in the apixaban group (hazard ratio, 0.47; 95% confidence interval, 0.25-0.92). There was not a statistical difference between time to thrombosis (83 days vs 54 days, P = .648), rate of thrombosis (5.5% vs 10.3%, P = .08), time to bleeding (46 days vs 54 days, P = .886), or rate of bleeding (5.5% vs 10.9%, P = .06). The severity of bleeding and thrombotic events was not different between groups. Apixaban may serve as a reasonable alternative compared with warfarin in patients with severe renal dysfunction.

Indexed as

AnticoagulantsKidney DiseasesPyrazolesPyridonesWarfarinFemaleHumansRetrospective StudiesAnticoagulantsapixabanPyrazolesPyridonesWarfarin

Identifiers

PMID32463871
PMCPMC7284084
OpenAlexW3029735202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.